While GLP1 receptor agonists have demonstrated utility in MASH, whether this translates into discernible improvements in major liver-related clinical outcomes (i.e., cirrhosis and clinical decompensation, transplant-free survival, HCC etc.)remains to be elucidated. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.